Inhibikase Therapeutics (IKT) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	IKT
Entity Registrant Name	INHIBIKASE THERAPEUTICS, INC.
Entity Central Index Key	0001750149
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		25,227,051
Entity File Number	001-39676
Entity Current Reporting Status	Yes
Entity Tax Identification Number	26-3407249
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	678
Local Phone Number	392-3419
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,781,918	$ 40,750,133
Marketable securities	20,752,290
Accounts receivable	13,842	110,141
Prepaid research and development	932,419	107,000
Prepaid expenses and other current assets	505,924	1,502,725
Total current assets	27,986,393	42,469,999
Equipment and improvements	241,574
Right-of-use asset	353,250
Total assets	28,581,217	42,469,999
Current liabilities:
Accounts payable	781,223	1,089,778
Lease obligation, current	142,048
Accrued expenses and other current liabilities	2,289,726	2,715,761
Notes payable	0	248,911
Total current liabilities	3,212,997	4,054,450
Lease obligations	232,020
Total liabilities	3,445,017	4,054,450
Commitments and contingencies (see Note 15)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 25,227,051 and 25,155,198 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	25,227	25,155
Additional paid-in capital	68,676,935	68,208,081
Accumulated other comprehensive income	26,828	0
Accumulated deficit	(43,592,790)	(29,817,687)
Total stockholders' equity	25,136,200	38,415,549
Total liabilities and stockholders' equity	$ 28,581,217	$ 42,469,999

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,227,051	25,155,198
Common stock, shares outstanding	25,227,051	25,155,198

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 7,291	$ 328,459	$ 59,874	$ 3,098,661
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember
Costs and expenses:
Research and development	$ 2,981,653	$ 3,154,553	$ 8,980,827	$ 7,968,846
Selling, general and administrative	1,538,737	1,644,946	4,872,681	4,854,494
Total costs and expenses	4,520,390	4,799,499	13,853,508	12,823,340
Loss from operations	(4,513,099)	(4,471,040)	(13,793,634)	(9,724,679)
Interest income	18,536	0	18,536	0
Interest expense	0	(157)	(5)	(19,765)
Net loss	(4,494,563)	(4,471,197)	(13,775,103)	(9,744,444)
Unrealized gains on marketable securities	26,828	0	26,828	0
Comprehensive loss	$ (4,467,735)	$ (4,471,197)	$ (13,748,275)	$ (9,744,444)
Net loss per share - basic	$ (0.18)	$ (0.18)	$ (0.55)	$ (0.61)
Net loss per share - diluted	$ (0.18)	$ (0.18)	$ (0.55)	$ (0.61)
Weighted average number of common share basic	25,227,051	25,143,559	25,219,931	15,868,421
Weighted Average Number of Shares Outstanding, Diluted	25,227,051	25,143,559	25,219,931	15,868,421

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Total	Offering	Common Stock	Common Stock Offering	Additional Paid-In Capital	Additional Paid-In Capital Offering	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		$ 24,805,929			$ (15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Stock-based compensation expense	591,124				591,124
Warrant expense	237,768				237,768
Issuance of common stock	60,391		$ 9		60,382
Issuance of common stock, Shares			9,000
Net loss	(2,637,068)							(2,637,068)
Ending balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203			(17,668,692)
Ending balance, Shares at Mar. 31, 2021			10,059,849
Beginning balance at Dec. 31, 2020	9,784,356		$ 10,051		24,805,929			(15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Warrant expense	658,945
Net loss	(9,744,444)
Ending balance at Sep. 30, 2021	43,161,479		$ 25,155		67,912,392			(24,776,068)
Ending balance, Shares at Sep. 30, 2021			25,155,198
Beginning balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203			(17,668,692)
Beginning balance, Shares at Mar. 31, 2021			10,059,849
Stock-based compensation expense	322,483				322,483
Warrant expense	239,415				239,415
Issuance of common stock		$ 41,135,357		$ 15,000		$ 41,120,357
Issuance of common stock, Shares				15,000,000
Issuance of common stock, stock options exercised	(43,295)		$ 74		(43,369)
Issuance of common stock, stock options exercised, Shares			73,496
Net loss	(2,636,179)							(2,636,179)
Ending balance at Jun. 30, 2021	47,054,352		$ 25,134		67,334,089			(20,304,871)
Ending balance, Shares at Jun. 30, 2021			25,133,345
Stock-based compensation expense	352,419				352,419
Warrant expense	181,762				181,762
Issuance of common stock, cashless warrant exercise Shares			21,853
Issuance of common stock, cashless warrant exercise	44,143		$ 21		44,122
Net loss	(4,471,197)							(4,471,197)
Ending balance at Sep. 30, 2021	43,161,479		$ 25,155		67,912,392			(24,776,068)
Ending balance, Shares at Sep. 30, 2021			25,155,198
Beginning balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081			(29,817,687)
Beginning balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Stock-based compensation expense	$ 123,229				123,229
Issuance of common stock	67,000		$ 50		66,950
Issuance of common stock, Shares			50,000
Issuance of common stock, stock options exercised	44,142		$ 22		44,120
Issuance of common stock, stock options exercised, Shares			21,853
Net loss	(4,640,601)							(4,640,601)
Ending balance at Mar. 31, 2022	34,009,319		$ 25,227		68,442,380			(34,458,288)
Ending balance, Shares at Mar. 31, 2022			25,227,051
Beginning balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081			(29,817,687)
Beginning balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Warrant expense	$ 0
Net loss	(13,775,103)
Ending balance at Sep. 30, 2022	$ 25,136,200		$ 25,227		68,676,935		26,828	(43,592,790)
Ending balance, Shares at Sep. 30, 2022	25,227,051		25,227,051
Beginning balance at Mar. 31, 2022	$ 34,009,319		$ 25,227		68,442,380			(34,458,288)
Beginning balance, Shares at Mar. 31, 2022			25,227,051
Stock-based compensation expense	132,767				132,767
Net loss	(4,639,939)							(4,639,939)
Ending balance at Jun. 30, 2022	29,502,147		$ 25,227		68,575,147			(39,098,227)
Ending balance, Shares at Jun. 30, 2022			25,227,051
Stock-based compensation expense	101,788				101,788
Other comprehensive income	26,828						26,828
Net loss	(4,494,563)							(4,494,563)
Ending balance at Sep. 30, 2022	$ 25,136,200		$ 25,227		$ 68,676,935		$ 26,828	$ (43,592,790)
Ending balance, Shares at Sep. 30, 2022	25,227,051		25,227,051

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (13,775,103)	$ (9,744,444)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,681	0
Stock-based compensation expense	357,784	1,266,026
Noncash lease expense	20,818	0
Noncash consulting fees	67,000	60,391
Noncash PPP loan forgiveness	0	(27,550)
Warrant expense	0	658,945
Changes in operating assets and liabilities:
Grants receivable	96,299	(217,482)
Prepaid expenses and other current assets	996,801	(486,551)
Prepaid research and development	(825,419)	509,975
Accounts payable	(308,555)	(1,166,879)
Accrued expenses and other current liabilities	(449,718)	1,272,076
Deferred revenue	23,683	(2,325,741)
Net cash used in operating activities	(13,794,729)	(10,201,234)
Investing activities
Purchases of investments - marketable securities	(20,725,462)	0
Purchases of equipment and improvements	(243,255)	0
Net cash used in investing activities	(20,968,717)	0
Financing activities
Proceeds from issuance of common stock	0	41,135,357
Issuance of common stock from exercise of stock options	44,142	78,500
Payment of employee taxes in connection with stock option exercise	0	(77,652)
Repayments of notes payable	(248,911)	(42,534)
Net cash (used in) provided by financing activities	(204,769)	41,093,671
Net (decrease) increase in cash and cash equivalents	(34,968,215)	30,892,437
Cash and cash equivalents at beginning of period	40,750,133	13,953,513
Cash and cash equivalents at end of period	5,781,918	44,845,950
Supplemental disclosures of cash flow information
Cash paid for interest	973	19,608
Non-cash financing activities
PPP loan forgiveness	$ 0	$ 27,550

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Inhibikase Therapeutics, Inc. (the “Company,” “we” or “our”) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease, or PD, and related disorders. The Company's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. In 2021, we commenced clinical development of IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor we believe can modify the course of Parkinson’s disease including its manifestation in the gastrointestinal tract, or GI. The U.S. Food and Drug Administration (“FDA”) review of the Phase 1/1b data and the protocol for the Phase 2a three-month dosing study resulted in the FDA agreeing with the Company’s view that it was appropriate for the Phase 2a study to begin, prompting the Company to initiate the Phase 2 study, the 201 trial, at the end of May 2022. We have opened 16 of 34 selected sites as of November 1, 2022, and 11 patients have randomized into the trial of 120 patients planned to be enrolled, with no serious adverse events observed to date. In October 2022, an Investigational New Drug Application ("IND") to expand use of IkT-148009 into the Parkinson’s-related disease Multiple System Atrophy ("MSA") was filed with the FDA. In November 2022, following review of the IND for IkT-148009 as a treatment for MSA, the FDA notified the Company that it was placing the IkT-148009 programs for Parkinson's disease and MSA on clinical hold. The FDA indicated it will provide an official clinical hold letter to Inhibikase within 30 days to explain the basis of this decision. The Company is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients. Our first example of this technology is IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat Stable phase Chronic Myelogenous Leukemia ("SP CML"). Pursuant to its IND which was cleared by the FDA in August 2022, IkT-001Pro will be evaluated in a two-part dose finding/dose equivalence study in up to 56 healthy volunteers. The study is designed to evaluate the steady-state pharmacokinetics of IkT-001Pro and determine the dose of IkT-001Pro equivalent to 400 mg imatinib mesylate, the standard-of-care dose for SP-CML. Following the study, Inhibikase will confer with the FDA and seek agreement on the requirements for the New Drug Application ("NDA") process following the proposed approval path for IkT-001Pro under the 505(b)(2) statute. The Company will simultaneously pursue a superiority study comparing the selected does of IkT-001Pro to standard-of-care 400 mg imatinib mesylate in SP-CML patients using a novel, two-period-wait-list-crossover-switching study.

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2022
Disclosure Of Liquidity And Going Concern [Abstract]
Liquidity	2. Liquidity The Company has recognized recurring losses. At September 30, 2022, the Company had working capital of $ 24,773,396 , an accumulated deficit of $ 43,592,790 , cash of $ 5,781,918 , marketable securities of $ 20,752,290 and accounts payable, accrued expenses and other current liabilities of $ 3,070,949 . The Company had active grants in the amount of $ 385,888 , of which $ 300,386 remained available in accounts held by the U.S. Treasury as of November 1, 2022. The future success of the Company is dependent on its ability to have the FDA lift the clinical hold on the Company's IkT-148009 programs for PD and MSA, successfully obtain additional working capital, obtain regulatory approval for and successfully launch and commercialize its product candidates and to ultimately attain profitable operations. Prior to its initial public offering in December 2020 (“IPO”), the Company had funded its operations primarily through cash received in connection with revenue from its various grant programs. In addition, in June 2021 and December 2020, the Company raised approximately $ 41.1 million and $ 14.6 million in working capital from its underwritten public offering (the “June 2021 Offering”) and its initial public offering IPO, respectively. The Company is subject to a variety of risks similar to other early-stage life science companies including, but not limited to, the successful development, regulatory approval, and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional working capital. The Company has incurred significant research and development expenses and general and administrative expenses related to its product candidate programs. The Company anticipates costs and expenses to increase in the future as the Company continues to develop its product candidates. The Company may seek to fund its operations through additional public equity, private equity, or debt financings, as well as other sources. However, the Company may be unable to raise additional working capital, or if it is able to raise additional capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to continue to develop its product candidates. The Company estimates that its working capital at September 30, 2022 is sufficient to fund its normal operations through February 2024. However, until the Company receives and evaluates the official clinical hold letter from the FDA, it is unable to fully evaluate the effect of the clinical hold on the Company’s liquidity. For example, if or when the clinical hold is lifted by the FDA, it is likely that the Company will have to recommence its IkT-148009 201 clinical trial for PD. In such event, the costs of completion of such clinical trial will be greater than originally anticipated. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	3. Basis of Presentation and Significant Accounting Policies Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2021 balance sheet was derived from December 31, 2021 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2022. The condensed unaudited consolidated financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. The unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly-owned subsidiary, IKT Securities Corporation, Inc., which was incorporated in the Commonwealth of Massachusetts in December 2021. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of its assertions made in connection with its assessment of liquidity and working capital adequacy, of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Concentrations of Credit Risk For the three and nine months ended September 30, 2022 and 2021 , the Company derived more than 90 % of its total revenue from a single source, the United States Government, in the form of federal research grants. Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s unaudited condensed consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received. Leases The Company accounts for its leases under ASU 2021-09, ASU 2018-10, and ASC Topic 842, Leases (“ASC 842”). ASC 842 requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the Company's balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases is required. Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease cost for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. Lease cost for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The Company has made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of operations and comprehensive loss over the lease term. Equipment and Improvements Equipment and improvements are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets. Estimated Useful Economic Life Leasehold property improvements, right of use assets Lesser of lease term or useful life Furniture and office equipment 5 years Lab equipment 3 Years IT equipment 3 years Fair Value Measurement The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. · Level 1 — Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access; · Level 2 — Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and · Level 3 — inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market based approaches, to determine value and improvements are stated at cost, less accumulated depreciation. Marketable Securities The Company's marketable securities consist of U.S. Treasury securities with maturities of less than one year which are classified as available-for-sale and included in current assets on the balance sheet. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity in accumulated other comprehensive income. Realized gains and losses, if any, are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments The following table summarizes cash equivalents and marketable securities measured at their fair value on a recurring basis as of September 30, 2022: Fair Value Measurements as of September 30, 2022 Using: Level 1 Level 2 Level 3 Total Assets U.S. Treasury obligations $ 20,752,290 $ — $ — $ 20,752,290 Total $ 20,752,290 $ — $ — $ 20,752,290 There were no marketable securities as of December 31, 2021.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	5. Marketable Securities Marketable securities consisted of the following at September 30, 2022: September 30, 2022 Amortized Cost Unrealized Gain Unrealized Loss Fair Value Marketable securities, available-for-sale: U.S. Treasury obligations $ 20,725,462 $ 50,836 $ ( 24,008 ) $ 20,752,290 Total $ 20,725,462 $ 50,836 $ ( 24,008 ) $ 20,752,290 As of September 30, 2022, the Company held two U.S. Treasury debt securities that were in an unrealized gain position totaling $ 50,836 and two U.S. Treasury debt securities that were in an unrealized loss position totaling $ 24,008 . There were no marketable securities as of December 31, 2021 .

Equipment and Improvements

Equipment and Improvements	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Equipment and Improvements	6. Equipment and Improvements Equipment and Improvements, net September 30, 2022 Furniture and office equipment $ 72,692 Lab equipment 153,668 IT equipment 16,895 243,255 Less: Accumulated Depreciation 1,681 Total $ 241,574

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Information	7. Supplemental Balance Sheet Information Accrued expenses and other current liabilities consist of the following: September 30, December 31, Accrued consulting $ 229,661 $ 210,000 Accrued compensation 417,573 421,734 Deferred revenue 23,683 — Accrued research and development 1,586,138 2,077,932 Accrued interest — 968 Accrued other 32,671 5,127 Total accrued expenses and other current liabilities $ 2,289,726 $ 2,715,761

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	8. Notes Payable Notes payable outstanding were $ 0 and $ 248,911 at September 30, 2022 and December 31, 2021, respectively. Note Payable to CEO On February 5, 2020 (the “Issue Date”), the Company issued a note payable to its CEO (the “CEO Note”) in the face amount of $ 245,250 bearing 1.59 % APR simple interest in exchange for cash. The net proceeds of $ 245,250 were used as working capital by the Company. The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note. If an event of default occurred and continued, the Company agreed to issue a warrant to the holder with a strike price of $ 4.87 per share for a number of shares equal to 150 % of the value of the loan. The Company assessed the terms and features of the CEO Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 13, 2020, the holder of the CEO Note and the Company entered into a restated agreement (the “CEO Restated Note”). The CEO Restated Note in the amount of $ 248,911 extended the stated maturity date of the CEO Note from the earlier of the sixth month following the (original) Issue Date or the date the Company has sufficient funds to repay the note to the earlier of the 30th month following the (original) Issue Date or the date the Company has sufficient funds to repay the CEO Restated Note. The Issue Date, February 5, 2020 , remained unchanged. In addition, the interest rate was reduced, effective as of the Issue Date, from 1.59 % APR to 0.25 %. The CEO Restated Note also changed the exercise price of the warrant from $ 4.87 to $ 4.81 per share in the case of any default. The other provisions of the CEO Restated Note remained the same, in all material respects, to the CEO Note. The Company and its CEO agreed that the CEO Restated Note would not be repaid for a minimum of 12 months following the closing of its initial public offering. The principal balance of the CEO Note was $ 248,911 at December 31, 2021. The principal balance plus accrued and unpaid interest on the CEO Note were settled in full, without adjustment, in cash on January 3, 2022.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. As of September 30, 2022, a total of 5,589,991 shares of common stock were reserved for issuance upon the exercise of outstanding stock options and warrants under the 2020 Equity Incentive Plan (the "2020 Plan") and the 2011 Equity Incentive Plan. Share Issuances In March 2021, a corporate accredited investor subscribed for, and the Company issued, 9,000 shares of its common stock in exchange for consulting services. The fair value of the common stock was $ 60,391 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. The $ 60,391 fair value was a component of selling, general and administrative costs for the nine months ended September 30, 2021. In connection with the June 2021 Offering, the Company issued and sold 15,000,000 fully paid non-assessable shares of its common stock at a public offering price of $ 3.00 per share. Proceeds from the June 2021 Offering were $ 41.1 million after deducting offering costs, underwriting discounts and commissions of approximately $ 3.9 million. In January 2022, the Company issued 21,853 shares of its common stock in connection with the exercise of non-qualified stock options with a strike price of $ 2.02 per share. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. This issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering. In February 2022, a corporate accredited investor subscribed for, and the Company issued, 50,000 shares of its common stock in exchange for consulting services. The fair value of the common stock was $ 67,000 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. This issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation 2020 Equity Incentive Plan The Company’s 2020 Plan was established for granting stock incentive awards to directors, officers, employees and consultants to the Company. Stock Options During the nine months ended September 30, 2022 , the Company granted 160,000 options to purchase its common stock to each of the members of its board of directors with a strike price of $ 0.81 per share and an aggregate grant date fair value of $ 82,492 . The options will cliff vest on the sooner to occur of one year from the June 24, 2022 grant date or the day prior to the 2023 annual meeting. On September 1, 2022, 40,000 of the 160,000 options were forfeited in connection with the resignation of a board member. The Company reversed prior stock compensation expense of $ 339 in connection with the forfeiture. During the nine months ended September 30, 2022 , the Company granted 239,887 options to purchase its common stock to certain employees. The employee grants will vest on each anniversary in equal parts over three years. The weighted average strike price and the aggregate grant date fair value of these options is $ 1.07 and $ 165,563 , respectively. During the nine months ended September 30, 2022 , 29,322 employee options were forfeited in connection with termination of employment. The Company reversed $ 8,399 of prior stock compensation expense in connection with this forfeiture. In addition, on September 1, 2022, the Company awarded an initial grant of 60,000 options to purchase common stock to a new member of the board of directors. This award will vest 50% on each of the first two anniversaries of the award. The strike price and fair value of this award is $ 0.95 and $ 37,225 , respectively. During the nine months ended September 30, 2021 , the Company granted 68,628 options to purchase common stock to its scientific advisory board members with a strike price of $ 6.82 per share, vesting immediately, with an aggregate grant date fair value of $ 259,674 . On June 25, 2021, the Company granted a total of 90,708 options to members of its board of directors with a strike price of $ 2.92 per share, vesting one year from the date of the grant, with an aggregate grant date fair value of $ 160,000 . On August 16, 2021, the Company granted 27,240 employee stock options with a strike price of $ 1.79 per share, vesting in three equal annual installments commencing on the first anniversary of the grant date, with a grant date fair value of $ 50,000 . Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Nine Months Ended September 30, 2022 2021 Research and development $ 98,722 $ 592,966 Selling, general and administrative 259,062 673,060 Total stock-based compensation expense $ 357,784 $ 1,266,026

Warrants

Warrants	9 Months Ended
	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	11. Warrants The Company recognized $ 181,762 and $ 658,945 in warrant expense for the three and nine months ended September 30, 2021 , respectively, included in selling, general and administration expense.

ATM Program

ATM Program	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
ATM Program	12. ATM Program On May 16, 2022, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Piper Sandler & Co. as sales agent (the “Agent”), pursuant to which the Company may, from time to time, issue and sell shares of its Common Stock, at an aggregate offering price of up to $ 9.8 million (the “Shares”) through the Agent. Under the terms of the Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, as amended. Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Agreement or terminate the Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a fixed commission of 3.0 % of the aggregate gross proceeds from the Shares sold. The Agreement contains customary representations and warranties, and the Company is required to deliver customary closing documents and certificates in connection with sales of the Shares. As of September 30, 2022, no Shares have been sold under the Agreement.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Nine Months Ended September 30, 2022 2021 Numerator: Net loss $ ( 13,775,103 ) $ ( 9,744,444 ) Denominator: Weighted-average number of common shares 25,219,931 15,868,421 Net loss per share applicable to common $ ( 0.55 ) $ ( 0.61 ) The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Nine Months Ended September 30, 2022 2021 Options to purchase shares of stock 4,028,078 3,630,044 Warrants to purchase shares of stock 1,561,913 1,561,913 Total 5,589,991 5,191,957

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes During the nine months ended September 30, 2022 and 2021 , there was no provision for income taxes as the Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company recorded a full valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Impact of the COVID-19 Pandemic on Our Operations There continues to be widespread impact from the COVID-19 pandemic. Beginning in the first quarter of 2021, there has been a trend in many parts of the world of increasing availability and administration of vaccines against COVID-19, as well as an easing of restrictions on social, business, travel and government activities and functions. On the other hand, infection rates and regulations continue to fluctuate in various regions and there are ongoing global impacts resulting from the pandemic, including challenges and increases in costs for logistics and supply chains. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location. In addition, we have experienced and are experiencing varying levels of inflation resulting in part from various supply chain disruptions, increased shipping and transportation costs, increased raw material and labor costs and other disruptions caused by the COVID-19 pandemic and general global economic conditions. The COVID-19 pandemic has caused significant, industry-wide delays in clinical trials. There are multiple causes of these delays, including reluctance of patients to enroll or continue in trials for fear of exposure to COVID-19, local and regional shelter-in-place orders and regulations that discourage, hamper, or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of COVID-19 patients and the FDA and other regulators making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to the pandemic. As a result of the COVID-19 pandemic, commencement of enrollment in our clinical trials may be delayed. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in the Company’s trials or are subject to isolation or shelter-in-place restrictions, this may cause them to drop out of the Company’s trials, miss scheduled doses or follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if the Company’s trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the Company’s trials may be compromised or not accepted by the FDA or other regulatory authorities, which could impact or delay a clinical development program. The Company anticipates that the COVID-19 pandemic may also impact manufacturing and distribution of materials necessary for the conductance of its clinical trials. Although the Company did not experience a material impact on its operations during the nine months ended September 30, 2022 and 2021, the Company notes the high level of difficulty in determining the future potential adverse financial impact and other effects of COVID-19 on the Company and its programs, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability would include probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. Lease On April 18, 2022, the Company entered into an operating lease agreement for office space at its new location in Lexington, Massachusetts (the "Office Lease"). On August 8, 2022, the Company commenced occupancy of the leased space. The lease runs through July 31, 2025 . The Company accounts for the Office Le ase under the provisions of ASU No. 2021-09, ASU 2018-10, and ASC 842. We recorded a right-of-use asset and a corresponding operating lease liability on the Company's condensed consolidated balance sheet upon the accounting commencement date in August 2022. The lease liability was measured at the accounting commencement date utilizing a 12 % discount rate. The right-of-use asset had a balance of $ 353,350 at September 30, 2022. The operating lease obligations totaled $ 374,068 at September 30, 2022 of which $ 142,048 is included under current liabilities and $ 232,020 is included under non-current liabilities . The Company recorded lease expense of $ 20,818 for the three and nine months ended September 30, 2022 included in selling, general and administrative expenses. The Office Lease contains escalating payments during the lease period. Upon execution of the Office Lease, the Company prepaid one month of rent and a security deposit, one of which will be held in escrow and credited at the termination of the lease and the other of which will be applied to the first month’s rent. As of September 30, 2022 , a security deposit of approximately $ 25,000 was included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheet related to the Office Lease. Future minimum lease payments under these leases at September 30, 2022, are presented by calendar year as follows: Year 2022 $ 33,469 2023 145,836 2024 150,095 2025 114,966 Total lease payments 444,366 Less: imputed interest 70,298 Present value of operating lease liabilities $ 374,068

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Minimum Bid Price of Common Stock On July 25, 2022, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $ 1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Notice”). The Minimum Bid Price Notice has no immediate effect on the continued listing status of the Company’s Common Stock on The Nasdaq Capital Market and, therefore, our listing remains fully effective. The Company is provided a compliance period of 180 calendar days from the date of the Minimum Bid Price Notice, or until January 23, 2023, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price Compliance Period”). If at any time before January 23, 2023 the closing bid price of the Company’s Common Stock closes at or above $ 1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement, and the matter would be resolved. If the Company does not regain compliance during the Minimum Bid Price Compliance Period, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided the Company (i) meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement, and (ii) notifies Nasdaq of its intent to cure the deficiency. As of November 14, 2022, the Company had not regained compliance with the Minimum Bid Price Requirement.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation of Interim Financial Statements	Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2021 balance sheet was derived from December 31, 2021 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2022. The condensed unaudited consolidated financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. The unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly-owned subsidiary, IKT Securities Corporation, Inc., which was incorporated in the Commonwealth of Massachusetts in December 2021. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of its assertions made in connection with its assessment of liquidity and working capital adequacy, of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk For the three and nine months ended September 30, 2022 and 2021 , the Company derived more than 90 % of its total revenue from a single source, the United States Government, in the form of federal research grants.
Revenue Recognition	Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s unaudited condensed consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.
Leases	Leases The Company accounts for its leases under ASU 2021-09, ASU 2018-10, and ASC Topic 842, Leases (“ASC 842”). ASC 842 requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the Company's balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases is required. Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease cost for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. Lease cost for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The Company has made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of operations and comprehensive loss over the lease term.
Equipment and Improvements	Equipment and Improvements Equipment and improvements are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets. Estimated Useful Economic Life Leasehold property improvements, right of use assets Lesser of lease term or useful life Furniture and office equipment 5 years Lab equipment 3 Years IT equipment 3 years Fair Value Measurement The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. · Level 1 — Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access; · Level 2 — Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and · Level 3 — inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market based approaches, to determine value and improvements are stated at cost, less accumulated depreciation.
Marketable Securities	Marketable Securities The Company's marketable securities consist of U.S. Treasury securities with maturities of less than one year which are classified as available-for-sale and included in current assets on the balance sheet. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity in accumulated other comprehensive income. Realized gains and losses, if any, are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Property plant estimate useful life	For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets. Estimated Useful Economic Life Leasehold property improvements, right of use assets Lesser of lease term or useful life Furniture and office equipment 5 years Lab equipment 3 Years IT equipment 3 years

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments [Table Text Block]	The following table summarizes cash equivalents and marketable securities measured at their fair value on a recurring basis as of September 30, 2022: Fair Value Measurements as of September 30, 2022 Using: Level 1 Level 2 Level 3 Total Assets U.S. Treasury obligations $ 20,752,290 $ — $ — $ 20,752,290 Total $ 20,752,290 $ — $ — $ 20,752,290

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities [Table Text Block]	Marketable securities consisted of the following at September 30, 2022: September 30, 2022 Amortized Cost Unrealized Gain Unrealized Loss Fair Value Marketable securities, available-for-sale: U.S. Treasury obligations $ 20,725,462 $ 50,836 $ ( 24,008 ) $ 20,752,290 Total $ 20,725,462 $ 50,836 $ ( 24,008 ) $ 20,752,290

Equipment and Improvements (Tab

Equipment and Improvements (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule Of Equipment and Improvements	Equipment and Improvements, net September 30, 2022 Furniture and office equipment $ 72,692 Lab equipment 153,668 IT equipment 16,895 243,255 Less: Accumulated Depreciation 1,681 Total $ 241,574

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consist of the following: September 30, December 31, Accrued consulting $ 229,661 $ 210,000 Accrued compensation 417,573 421,734 Deferred revenue 23,683 — Accrued research and development 1,586,138 2,077,932 Accrued interest — 968 Accrued other 32,671 5,127 Total accrued expenses and other current liabilities $ 2,289,726 $ 2,715,761

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees	The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Nine Months Ended September 30, 2022 2021 Research and development $ 98,722 $ 592,966 Selling, general and administrative 259,062 673,060 Total stock-based compensation expense $ 357,784 $ 1,266,026

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders	The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Nine Months Ended September 30, 2022 2021 Numerator: Net loss $ ( 13,775,103 ) $ ( 9,744,444 ) Denominator: Weighted-average number of common shares 25,219,931 15,868,421 Net loss per share applicable to common $ ( 0.55 ) $ ( 0.61 )
Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders	The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Nine Months Ended September 30, 2022 2021 Options to purchase shares of stock 4,028,078 3,630,044 Warrants to purchase shares of stock 1,561,913 1,561,913 Total 5,589,991 5,191,957

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under these leases at September 30, 2022, are presented by calendar year as follows: Year 2022 $ 33,469 2023 145,836 2024 150,095 2025 114,966 Total lease payments 444,366 Less: imputed interest 70,298 Present value of operating lease liabilities $ 374,068

Liquidity - Additional Informat

Liquidity - Additional Information (Details) - USD ($)		3 Months Ended
	Nov. 01, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital					$ 24,773,396
Accumulated deficit					(43,592,790)	$ (29,817,687)
Cash and cash equivalents					5,781,918	$ 40,750,133
Accounts payable and accrued expenses					20,752,290
other current liabilities					$ 3,070,949
Issuance of common stock	$ 385,888	$ 67,000		$ 60,391
Treasury share held	$ 300,386
June 2021 Offering
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital			$ 41,100,000
Issuance of common stock			$ 41,135,357
IPO
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital							$ 14,600,000

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value	$ 0.001		$ 0.001	$ 0.001
Minimum | Network Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P3Y
Minimum | Office Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P3Y
Minimum | Furniture
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P3Y
Maximum | Network Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P5Y
Maximum | Office Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P5Y
Maximum | Furniture
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P5Y
Customer Concentration Risk | Sales Revenue | Minimum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	90%	90%

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - classified as fixed assets useful life (Details)	9 Months Ended
	Sep. 30, 2022
Leasehold property improvements, right of use asset
Property, Plant and Equipment [Line Items]
Estimated useful lives	Lesser of lease term or useful life
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Economic Life	5 years
Lab equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Economic Life	3 years
IT equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Economic Life	3 years

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of cash equivalents and marketable securities measured at their fair value (Details) - Fair Value, Recurring [Member]	Sep. 30, 2022 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	$ 20,752,290
U.S. Treasury obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	20,752,290
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	20,752,290
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	20,752,290
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	0
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Additional Information) (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Marketable securities	$ 20,752,290	$ 0

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Marketable securities, available-for-sale:
Marketable securities, Amortized cost	$ 20,725,462
Marketable securities, Unrealized Gain	50,836
Marketable securities, Unrealized Loss	(24,008)
Marketable securities, Fair Value	20,752,290	$ 0
U.S. Treasury obligations
Marketable securities, available-for-sale:
Marketable securities, Amortized cost	20,725,462
Marketable securities, Unrealized Gain	50,836
Marketable securities, Unrealized Loss	(24,008)
Marketable securities, Fair Value	$ 20,752,290

Marketable securities (Addition

Marketable securities (Additional Information) (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Gain (Loss) on Securities [Line Items]
Unrealized gain	$ 50,836
Marketable securities, Unrealized Loss	(24,008)
U.S. treasury debt securities
Gain (Loss) on Securities [Line Items]
Unrealized gain	50,836
Marketable securities, Unrealized Loss	(24,008)
U.S. treasury debt securities | One Debt
Gain (Loss) on Securities [Line Items]
Unrealized gain	50,836
U.S. treasury debt securities | Two Debt
Gain (Loss) on Securities [Line Items]
Marketable securities, Unrealized Loss	$ (24,008)

Equipment and Improvements - Sc

Equipment and Improvements - Schedule of Equipment and Improvements (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment, Gross	$ 243,255
Less: Accumulated Depreciation	1,681
Total	241,574
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	72,692
Lab equipment [Member]
Property, Plant and Equipment, Gross	153,668
IT equipment [Member]
Property, Plant and Equipment, Gross	$ 16,895

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued consulting	$ 229,661	$ 210,000
Accrued compensation	417,573	421,734
Deferred revenue	23,683	0
Accrued research and development	1,586,138	2,077,932
Accrued interest	0	968
Accrued other	32,671	5,127
Total accrued expenses and other current liabilities	$ 2,289,726	$ 2,715,761

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)		3 Months Ended	9 Months Ended
	Feb. 05, 2020	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Jun. 13, 2020
Debt Instrument [Line Items]
Annual interest rate	1.59%
Common stock, par value			$ 0.001	$ 0.001
Notes payable outstanding balance			$ 0	$ 248,911
Strike price	$ 4.87
Issue date	Feb. 05, 2020
Principal Balance
Debt Instrument [Line Items]
Notes payable, net of current portion				$ 248,911
CEO Note
Debt Instrument [Line Items]
Annual interest rate	1.59%
Debt instrument face amount	$ 245,250
Net proceeds	$ 245,250
Maturity description			The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note.
Strike price	$ 4.87
Percentage of number of shares to value of loan	150%
On event of default		If an event of default occurred and continued, the Company agreed to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan.
C E O Restated Note
Debt Instrument [Line Items]
Annual interest rate					0.25%
Debt instrument face amount					$ 248,911
Strike price					$ 4.81

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)	1 Months Ended			6 Months Ended	9 Months Ended
	Feb. 28, 2022 USD ($) shares	Jan. 31, 2022 $ / shares shares	Mar. 31, 2021 USD ($) shares	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) Vote $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 $ / shares
Class Of Stock [Line Items]
Votes per each common stock share | Vote					1
Common stock shares reserved for issuance					5,589,991
Common stock, par value | $ / shares					$ 0.001		$ 0.001
Proceeds from issuance of common stock | $					$ 0	$ 41,135,357
Additional rights or options granted		0
Common stock in connection with exercise of non-qualified stock options, Shares		21,853
Stock option strike price | $ / shares		$ 2.02
Consulting Services
Class Of Stock [Line Items]
Additional rights or options granted	0		0
Shares issued in exchange for consulting services	50,000		9,000
Fair value of stock issued in exchange for consulting services | $	$ 67,000		$ 60,391
Consulting Services | Selling, General and Administrative
Class Of Stock [Line Items]
Fair value of stock issued in exchange for consulting services | $			$ 60,391
June 2021 Offering
Class Of Stock [Line Items]
Shares issued price per share | $ / shares				$ 3
Proceeds from issuance of common stock | $				$ 41,100,000
Issued and sold fully paid non-assessable shares of common stock				15,000,000
Offering costs, underwriting discounts and commissions | $				$ 3,900,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)				6 Months Ended	9 Months Ended
	Sep. 01, 2022	Aug. 16, 2021	Jun. 25, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of stock options granted				68,628	160,000
Number of stock issued					239,887
Stock option, strike price				$ 6.82
Stock option, aggregate grant date fair value				$ 259,674
Stock compensation expense					$ 357,784	$ 1,266,026
Stock option granted for forfeited shares	40,000
Employee stock plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of stock options granted		27,240
Stock option, strike price		$ 1.79
Stock option, aggregate grant date fair value		$ 50,000
Stock option granted for forfeited shares					29,322
Board of Director Member
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of stock options granted			90,708
Stock option, strike price			$ 2.92		$ 0.81
Stock option, aggregate grant date fair value			$ 160,000		$ 82,492
Stock compensation expense					$ 339
Stock option granted for forfeited shares	160,000
Employee
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock option, strike price					$ 1.07
Stock option, aggregate grant date fair value					$ 165,563
Stock compensation expense					$ 8,399
New board of Director | Employee stock plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of stock options granted	60,000
Stock option, strike price	$ 0.95
Stock option, aggregate grant date fair value	$ 37,225

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 357,784	$ 1,266,026
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	98,722	592,966
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 259,062	$ 673,060

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Feb. 05, 2020
Class Of Warrant Or Right [Line Items]
Strike price						$ 4.87
Warrant expense	$ 181,762	$ 239,415	$ 237,768	$ 0	$ 658,945
Selling, General and Administrative
Class Of Warrant Or Right [Line Items]
Warrant expense	$ 181,762				$ 658,945

ATM Program (Additional Informa

ATM Program (Additional Information) (Details) - Equity Distribution Agreement - USD ($) $ in Millions	May 16, 2022	Sep. 30, 2022
Marketable Securities [Line Items]
Common stock Aggregate offering price	$ 9.8
Fixed commission percentage		3%

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss	$ (4,494,563)	$ (4,639,939)	$ (4,640,601)	$ (4,471,197)	$ (2,636,179)	$ (2,637,068)	$ (13,775,103)	$ (9,744,444)
Denominator:
Weighted average number of common share basic	25,227,051			25,143,559			25,219,931	15,868,421
Weighted average number of common share Diluted	25,227,051			25,143,559			25,219,931	15,868,421
Net loss per share applicable to common stockholders - basic	$ (0.18)			$ (0.18)			$ (0.55)	$ (0.61)
Net loss per share applicable to common stockholders - diluted	$ (0.18)			$ (0.18)			$ (0.55)	$ (0.61)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	5,589,991	5,191,957
Options to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	4,028,078	3,630,044
Warrants to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	1,561,913	1,561,913

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0

Commitments and Contingencies_2

Commitments and Contingencies (Additional Information) (Details) - USD ($)		3 Months Ended	9 Months Ended
	Apr. 18, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Lessor, Lease, Description [Line Items]
Right-of-use asset		$ 353,250	$ 353,250
Operating Lease, Liability, Current		142,048	142,048
Operating Lease, Liability, Noncurrent		232,020	232,020
Lease Expense		20,818	20,818
Operating lease Obligation		374,068	374,068
Prepaid Expenses and Other Current Assets [Member]
Lessor, Lease, Description [Line Items]
Security deposit		$ 25,000	$ 25,000
Lexington
Lessor, Lease, Description [Line Items]
Lease Expiration Date	Jul. 31, 2025
Lessee, Operating Lease, Discount Rate		12%	12%
Right-of-use asset		$ 353,350	$ 353,350
Lessor, Operating Lease, Description	The Office Lease contains escalating payments during the lease period. Upon execution of the Office Lease, the Company prepaid one month of rent and a security deposit, one of which will be held in escrow and credited at the termination of the lease and the other of which will be applied to the first month’s rent.

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future minimum lease payments (Details)	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 33,469
2023	145,836
2024	150,095
2025	114,966
Total lease payment	444,366
Less: imputed interest	70,298
Present value of operating lease liabilities	$ 374,068

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - $ / shares	1 Months Ended	9 Months Ended
	Jul. 25, 2022	Sep. 30, 2022
Subsequent Event [Line Items]
Closing Price of Common Stock	$ 1	$ 1
Subsequent Event, Description	On July 25, 2022, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Notice”).	The Company is provided a compliance period of 180 calendar days from the date of the Minimum Bid Price Notice, or until January 23, 2023, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price Compliance Period”). If at any time before January 23, 2023 the closing bid price of the Company’s Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement, and the matter would be resolved.